Skip to content

VRTX

Vertex Pharmaceuticals Incorporated

Income statement

Income statement
Line, in USDLast 12 months202520242023202220212020201920182017201620152014201320122011201020092008
Revenue13.0B12.0B11.0B9.9B8.9B7.6B6.2B4.2B3.0B2.5B1.7B1.0B580M1.2B1.5B1.4B143M102M176M
Cost of revenue
1.87B1.65B1.53B1.26B1.08B0.90B0.74B0.55B0.41B0.28B0.21B0.12B40M89M0.24B64M0——
Gross profit11.1B10.4B9.5B8.6B7.9B6.7B5.5B3.6B2.6B2.2B1.5B915M541M1.1B1.3B1.3B143M——
4.25B3.91B3.63B3.16B2.54B3.05B1.83B1.75B1.42B1.32B1.05B1.00B0.86B0.88B0.77B0.71B0.64B0.55B0.52B
2.41B1.75B1.46B1.14B0.94B0.84B0.77B0.66B0.56B0.50B0.43B0.38B0.31B0.36B0.43B0.40B0.19B0.13B0.10B
Other operating expenses
0.12B0.51B4.63B0.48B58M—13M4.5M29M0.27B—9.6M72M0.49B45M0.12B14M——
Operating income4.30B4.17B−0.23B3.83B4.31B2.78B2.86B1.20B0.64B0.12B9.9M−0.47B−0.69B−0.61B47M0.11B−0.70B−0.61B−0.46B
Non-operating income
455M470M481M548M−75M−52M261M197M−35M−139M−77M−91M−42M−16M−15M−53M−59M−28M2.9M
Pretax income4.76B4.64B0.25B4.38B4.23B2.73B3.12B1.39B0.60B−16M−67M−0.56B−0.73B−0.63B32M60M−0.75B−0.64B−0.46B
Taxes
0.78B0.69B0.78B0.76B0.91B0.39B0.41B0.22B−1.50B−0.28B45M−1.5M3.7M−0.18B0.14B31M000
Net income3.98B3.95B−0.54B3.62B3.32B2.34B2.71B1.18B2.10B0.26B−0.11B−0.56B−0.74B−0.45B−0.11B30M−0.75B−0.64B−0.46B
Diluted EPS15.5415.32−2.0813.8912.829.0110.294.518.091.04−0.46−2.31−3.14−1.98−0.500.14−3.77−3.71−3.27
Diluted shares—258.0M257.9M260.5M259.1M259.9M263.4M260.7M259.2M253.2M244.7M241.3M235.3M224.9M215.3M208.8M200.4M173.3M140.6M
Revenue growth—+8.9%+11.7%+10.5%+17.9%+22.1%+49.1%+36.6%+22.5%+46.2%+64.9%+77.9%−52.1%−20.6%+8.3%+883.9%+40.7%−41.9%—
Gross margin85.5%86.2%86.1%87.2%87.9%88.1%88.1%86.8%86.6%88.9%87.6%88.7%93.2%92.7%84.5%95.5%100.0%——
Operating margin33.2%34.8%−2.1%38.8%48.2%36.7%46.0%28.8%20.8%5.0%0.6%−45.2%−119.3%−50.3%3.1%8.1%−485.5%−602.6%−263.6%
Net margin30.7%32.9%−4.9%36.7%37.2%30.9%43.7%28.3%68.8%10.6%−6.6%−53.9%−127.2%−36.7%−7.0%2.1%−526.3%−630.3%−262.0%